ARID5B

Across TCGA pan-cancer cohorts, ARID5B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ARID5B’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ARID5B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ARID5B is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

LSCC, HNSC, and PDAC are the cancer types where ARID5B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARID5B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	+0.231	<.001	8	view →
HNSC	All	III,IV	−0.197	.017	4	view →
PDAC	Female	II,III,IV	+0.336	.013	2	view →
CCRCC	All	All	+0.182	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ARID5B–LSCC

Open the LSCC breakdown →